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At 5.5 years, initial SNM therapy was less costly ($23,504 vs. $27,720) and more
effective than initial BTX (4.08 vs. 4.04 QALYs). Probabilistic sensitivity analyses
that varied SNM and BTX success and repeat BTX injection probabilities and utili-
ties, confirmed these results. Repeat injections and differences in AEswere respon-
sible for most of the changing costs over time. CONCLUSIONS: Based on a more
clinically comprehensive design and set of inputs than previousmodels, treatment
with SNM may be more cost-effective than BTX, especially over longer periods of
time.
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OBJECTIVES: Hyperphosphatemia leads to increased hospitalizations and mortal-
ity in End-Stage Renal Disease (ESRD). First-line therapy in Canada consists primar-
ily of calcium carbonate (CC). We determined the incremental cost-effectiveness
ratio (ICER) of the non-calcium phosphate binder lanthanum carbonate (LC) as
second-line therapy, from a Canadian healthcare perspective. METHODS: A
Markov model was developed to determine the cost-effectiveness of second-line
LC after therapy failure on CC, compared with continued CC treatment; or alterna-
tively with second-line Sevelamer (SH). Patient-level data (n380) from a prospec-
tive randomized trial were used for LC and CC drug efficacy. For SH efficacy, an
indirect comparison of eight clinical trials was used to calculate a dose-relativity
between SHand LC of 2.7:1. Costs, quality of life,mortality andhospitalization rates
were based on Canadian data. Univariate and probabilistic sensitivity analyses
were performed. RESULTS: Modelling 1,000 dialysis patients, 378 (37.8%) did not
achieve target serum phosphate (SP) levels (1.78 mmol/L) with first-line CC ther-
apy and were eligible for LC. Of these, 168 (44.4%) responded to LC therapy, result-
ing in 49 life years and 29 Quality-adjusted life years (QALYs) gained. The ICER of
second-line LC treatment comparedwith continuedCC treatmentwasCAN$13,200
($4,600-$22,800) per QALY gained. Results were robust to plausible variations in
model parameters. One-year drug costs per additional responder to second-line LC
therapy were $2,600, compared to $4,300 for first-line LC. The model evaluating
second-line use of LC vs second-line use of SH estimated that LC had similar effi-
cacy but was 16% less expensive than SH. CONCLUSIONS: Second-line treatment
with LC is cost-effective compared to continued therapy with CC; and is less ex-
pensive compared to first-line LC. LC had lower costs compared with SH, due to
lower dose requirements for similar efficacy. These results reinforce current treat-
ment guidelines to treat patients not achieving target SP levels on CC with second-
line LC.
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OBJECTIVES: Cytomegalovirus (CMV) disease can severely impact patient out-
comes and costs associated with kidney transplant. The IMPACT study has shown
that kidney transplant patients significantly benefit from extending valganciclovir
prophylaxis from 100 to 200 days. The objective of this study was to determine the
cost-effectiveness of valganciclovir 200 day prophylaxis compared to 100 days in
kidney transplant patients at high-risk for developing CMV disease. METHODS: A
Markov model was developed to capture time spent by patients in various health
states, which included: CMV, No-CMV, Acute Rejection, Graft Failure, Dialysis and
Death. Results were reported as incremental cost per additional quality adjusted
life-years (QALY) gained, over a 10-year period. Transition probabilities for the first
year were derived from the IMPACT study. Data beyond the first year were derived
from the published literature and baselinemortality rate was determined from the
Canadian Organ Replacement Register. The base case analysis focused on direct
medical costs only from the perspective of the Ministry of Health (MoH). A second
analysis was conducted from the societal perspective. Cost data were obtained
froma variety of sources and reported as 2010 CanadianDollars. A 5%discount rate
was applied to both costs and patient outcomes. Multiple sensitivity analyses were
undertaken to test the robustness of the model. RESULTS: From the MoH perspec-
tive valganciclovir 200 days prophylaxis is cost-effective when compared to 100
days with an incremental cost-utility ratio (ICUR) of $34,818 per additional QALY
gained. The cost-effectiveness is improved from the societal perspective, with an
ICUR of $32,571 per additional QALY gained. Results were robust over a wide range
of sensitivity analyses tested. CONCLUSIONS: Valganciclovir 200 days is a cost-
effective prophylaxis strategy in kidney transplant patients at high-risk of devel-
oping CMV when compared to valganciclovir 100 days.
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OBJECTIVES: The rate and extent of utilization of IV iron in anemic CKD patients
was quantified. Predictors of IV iron and ESAusewere determined. The impact of IV
iron and ESA use was examined separately for total hospital costs and length of
stay (LOS).METHODS: This is a retrospective cohort analysis within the UHC data
warehouse in the period of January 1, 2006, to December 31, 2008. Inclusion criteria
were age  18 years with a primary/secondary diagnosis of CKD. The exposure of
interest was IV iron and ESA therapy, and the outcome was the difference in total
hospital costs and length of stay. A binomial logistic regression using the GEE
methodology was used to identify predictors of IV iron utilization. Propensity
scores were used to control for confounding. A GEE model using gamma distribu-
tion and log link was used to determine the adjusted hospital cost and length of
stay for the IV iron and ESA and ESA alone therapy groups. RESULTS: 82,947 pa-
tients met the study criteria. Of the 82,947 CKD patients on ESA therapy, only 8%
(n  6678) patients were on IV iron supplementation. Age, race, primary payer,
admission status, severity of illness, dialysis status and physician specialty were
identified as strong predictors of IV ironuse. For patients using both IV iron and ESA
(n6678), mean costs were $34,756 compared to $31,404 for ESA users alone
(n76,269). The overall mean LOS for all patients was 9.75 days. For those using IV
iron, the LOS was 10.71 days, and for those only using ESA, the LOS was 9.66 days.
CONCLUSIONS: Our investigation showed significant reduction in ESA doses with
the use of IV iron supplementation, however, the overall prevalence of IV iron
usage was low. Intravenous iron users were associated with a higher total hospital
cost and longer length of stay than ESA users.
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OBJECTIVES: The aim of our study was to construct the conceptual framework of
the impact of ADPKD on patients to support the use or development of a HRQoL
instrument in ADPKD.METHODS: Based on concepts identified from the literature
and ADPKD physicians/researchers from North America, Europe, and Japan, pa-
tients were asked how ADPKD impacts their physical and social functioning, emo-
tions, and urinary symptoms according to a pre-defined moderator guide. Twenty
focus groups (FGs) were conducted across 11 sites: three cities in North America
(n42), six cities in Europe (n64), and two cities in Japan (n11). FGs were mod-
erated by native speakers and overseen onsite by a US-based scientist. A saturation
table was developed to summarize concepts discussed in the FGs; saturation was
achieved once no new concepts were identified. Concepts were identified based on
themes mentioned by 2 participants within a FG. RESULTS: Concepts generated
from the literature and ADPKD physicians/researchers discussions were endorsed
by ADPKD patients. Agreement of concepts between genders across all countries
was observed. Twenty-eight concepts were identified and categorized into: Physi-
cal Impact (impact on work/housework, limited functioning with mild/moderate
exertion, self-care, diminish sex/intimacy, pain/discomfort in extremities/core,
pain affecting work/housework, pain occurring with activity, modifications in life-
style), Emotional Impact (fatigue, depression, anxiety, guilt of passing it to children,
acceptance/self-education), Urinary Concerns (urgency, frequency, nocturia).
Other concepts identified by patients include effect on diet, concern over body
image, thirst, and disruption of social/leisure activities. Fifty-seven percent of
these concepts were identified in the first FG; 100% saturation was achieved in the
fifth FG. CONCLUSIONS: Identified concepts were universally applicable and their
strength is evident by the achievement of complete saturation after 25% of the FGs.
The completion of this conceptual framework using an iterative process provides a
strong basis to develop an ADPKD-specific HRQoL instrument.
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OBJECTIVES: The aim of this study was to characterize Brazilian-specific immuno-
suppressant (IS) treatment patterns among kidney transplant patients.METHODS:
Non-interventional, multicenter, medical chart review of patients undergoing kid-
ney transplant. Five year follow-up data on IS medication use from adult ( 18
years old at time of transplantation), single kidney only transplants from Jan/2004
to Jan/2005 were collected from 7 transplant center in Brazilian hospitals. Patients
were censored on graft loss or loss of follow-up. RESULTS: Data on 498 patients
were included; 51.2%were female, the, average age was 38.913.9 years, and 55.4%
was recipients of kidneys from deceased donors. Of the 498 patients, 61.2% were
treatedwith tacrolimus (TAC)-based IS regimens as the initial calcineurin inhibitor
(CNI), while 38.8%were treatedwith cyclosporine (CyC). CNI switching fromTAC to
CyC occurred in 4.6%, versus 5.6% that switched from CyC to TAC. There was a
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